Found Weight Loss: Specific Patient Profiles Who Should Avoid This Platform

What Is Found and How Does Its Care Model Work?

Found operates as a telehealth platform focused on anti-obesity medication (AOM) management. Patients complete an online intake form, speak with a clinician via video or asynchronous messaging, and receive prescriptions for medications that may include semaglutide, tirzepatide, bupropion/naltrexone (Contrave), topiramate, or metformin. The platform has partnered with Blue Cross Blue Shield affiliates to expand insurance coverage access.

How Prescribing Actually Happens

The intake evaluation is largely self-reported. Unlike a hospital obesity medicine clinic, Found does not routinely obtain an in-office physical exam, fasting metabolic panel, or EKG before initiating therapy. The clinician reviews the intake questionnaire and a brief synchronous or asynchronous encounter, then prescribes if the patient clears screening filters.

This model works well for otherwise healthy adults with straightforward obesity and no significant comorbidities. It creates real risk for patients whose baseline health complexity demands more than a 15-minute telehealth encounter to evaluate safely.

Medications Found Prescribes and Their Regulatory Status

Found's formulary sits at the intersection of several drug classes with distinct safety profiles:

• Semaglutide (Wegovy) and tirzepatide (Zepbound): FDA-approved for chronic weight management; carry a boxed warning for thyroid C-cell tumors in rodents and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2) [1].
• Bupropion/naltrexone (Contrave): FDA-approved for chronic weight management; carries a boxed warning for neuropsychiatric events and suicidality, primarily in patients under 25 [2].
• Topiramate (off-label): Teratogenic (FDA Pregnancy Category D); causes cognitive side effects and carries risk of metabolic acidosis [3].

The FDA prescribing information for each of these agents specifies the clinical evaluations that should precede initiation [1][2][3]. Asynchronous telehealth models may not capture all necessary pre-treatment data reliably.

Is Found Legit? Regulatory and Accreditation Standing

Found is a legitimate, registered telehealth company, not a scam. Its clinicians hold state-issued prescribing licenses, and it does not compound controlled substances in violation of FDA policy. "legit" and "appropriate for every patient" are different questions.

BBB Record and Consumer Complaints

Found holds BBB accreditation as of mid-2025. The BBB file includes multiple consumer complaints centered on billing disputes, difficulty canceling subscriptions, and medication delays. These are operational complaints, not clinical safety findings, but they are relevant to a patient deciding whether to commit to an ongoing medication regimen that requires consistent follow-up. Billing disruptions that interrupt GLP-1 supply can cause rebound weight gain; data from the STEP-4 trial (N=803) showed a 6.9% mean weight regain within 48 weeks of semaglutide discontinuation [4].

LegitScript and State Licensing

LegitScript, the pharmacy verification body that Google and Visa use to vet online prescribers, does review telehealth platforms. Patients can verify a platform's LegitScript status directly at legitscript.com. State medical boards govern the individual clinicians on Found's network; a patient can verify a prescriber's license through their state board website. The Federation of State Medical Boards maintains a public physician data center at fsmb.org.

What "Legit" Does Not Guarantee

Regulatory compliance does not equal individualized care. The American Association of Clinical Endocrinology (AACE) 2023 Clinical Practice Guideline for Obesity states: "Obesity is a chronic, relapsing, multifactorial disease that requires comprehensive and individualized treatment" [5]. A compliant telehealth intake form is not equivalent to the comprehensive evaluation AACE describes.

Patient Profile 1: History of Medullary Thyroid Carcinoma or MEN2

This is a hard contraindication. Semaglutide and tirzepatide are contraindicated, not cautioned, contraindicated, in patients with a personal or family history of MTC or MEN2 [1]. GLP-1 receptor agonists stimulate thyroid C-cell proliferation in rodent studies, and the clinical significance in humans remains under long-term study.

Why Telehealth Intake May Miss This

Family history of MTC is underrecognized by patients. Many people do not know a first-degree relative's cancer subtype. An asynchronous form asking "do you have a family history of thyroid cancer?" may return a false negative if the relative was diagnosed with MTC but the patient recalls only "thyroid cancer."

Patients with any personal or family history of thyroid cancer should see an endocrinologist before initiating any GLP-1 agonist, regardless of platform. The Endocrine Society's clinical guidelines on thyroid nodules provide relevant evaluation criteria [6].

Patient Profile 2: Active or Recent Eating Disorder

Patients with a current or recent history of anorexia nervosa, bulimia nervosa, or binge eating disorder require specialist involvement before any AOM is initiated. The FDA label for Contrave explicitly lists anorexia nervosa and bulimia nervosa as contraindications to bupropion use [2]. GLP-1 agonists, while not formally contraindicated in eating disorders, suppress appetite so profoundly that they may precipitate restrictive relapse in a recovering anorexic patient, or mask the behavioral drivers of binge eating disorder without addressing them.

The Evidence Gap

No large randomized controlled trial of semaglutide or tirzepatide has enrolled patients with active DSM-5 eating disorders as a primary population. STEP-1 (N=1,961) excluded patients with eating disorders at baseline [7]. SURMOUNT-1 (N=2,539) similarly excluded them [8]. Clinicians should not extrapolate safety data from trials that specifically excluded this population.

A telehealth intake screen asking "do you have an eating disorder?" is not a validated eating disorder screening instrument. The SCOFF questionnaire or EDE-Q are standard validated tools; Found's public-facing intake does not appear to use either.

What These Patients Need Instead

An eating disorder dietitian, a psychiatrist or psychologist with eating disorder training, and a physician comfortable managing medical complications of eating disorders should all be involved before any AOM is prescribed. The Academy for Eating Disorders publishes treatment guidelines at aedweb.org.

Patient Profile 3: Uncontrolled or Unstable Psychiatric Illness

Bupropion lowers seizure threshold and carries a boxed warning for suicidality [2]. Naltrexone can precipitate opioid withdrawal. The combination, Contrave, requires a careful psychiatric history and current medication review. Patients on monoamine oxidase inhibitors (MAOIs) cannot take bupropion at all; the combination risks hypertensive crisis [2].

Specific Psychiatric Contraindications for Found's Formulary

The FDA label for bupropion identifies the following contraindications relevant to psychiatric history [2]:

• Current or prior diagnosis of seizure disorder
• Current use of MAOIs or within the prior 14 days
• Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs
• Current or prior diagnosis of bulimia or anorexia nervosa

Topiramate, sometimes used off-label at Found, produces cognitive slowing and word-finding difficulty, side effects that are particularly new for patients with baseline cognitive impairment, depression, or anxiety [3].

What Asynchronous Intake Misses

A 2021 analysis published in JAMA Psychiatry found that self-reported psychiatric history in digital health platforms agreed with structured clinical interviews only about 74% of the time [9]. That 26% gap is clinically meaningful when prescribing a drug with a suicidality boxed warning.

Patients with active major depressive disorder, bipolar disorder, schizophrenia, or any condition requiring a psychiatrist should get psychiatric clearance before starting bupropion-containing regimens, regardless of platform.

Patient Profile 4: Personal or Family History of Pancreatitis

GLP-1 receptor agonists carry a warning, not a full contraindication, for pancreatitis risk. The FDA label for semaglutide (Wegovy) states that the drug should be discontinued if pancreatitis is suspected, and should not be restarted if pancreatitis is confirmed [1]. AACE guidelines recommend that patients with a prior episode of acute pancreatitis or chronic pancreatitis be evaluated carefully before GLP-1 initiation [5].

What the Data Show

A 2022 nested case-control study (N=1.2 million) published in Diabetes Care found no significant increase in acute pancreatitis with GLP-1 agonist use overall (adjusted OR 1.05, 95% CI 0.87 to 1.26), though subgroup analyses in patients with prior pancreatitis showed a trend toward higher risk that did not reach statistical significance [10]. The point is not that GLP-1s are unsafe in every patient with a pancreatitis history; it is that these patients require individualized assessment that goes beyond a self-reported online intake.

Found's intake may ask about prior pancreatitis, but the follow-up clinical reasoning, weighing gallstone disease, alcohol use, hypertriglyceridemia, genetic predisposition, is the kind of multi-variable evaluation that benefits from in-person workup, including fasting triglycerides and abdominal imaging history review.

Patient Profile 5: Pregnancy, Planned Pregnancy, or Breastfeeding

All GLP-1 agonists carry a Pregnancy Category warning. The FDA label for semaglutide advises discontinuing the drug at least two months before a planned pregnancy [1]. Animal data show embryotoxicity at clinically relevant exposures. Topiramate is FDA Pregnancy Category D and associated with cleft palate and intrauterine growth restriction at therapeutic doses [3].

The Discontinuation Window Matters

Two months is the recommended washout before conception for semaglutide; tirzepatide's label recommends the same [1][11]. Women of reproductive age on Found's platform who are not using reliable contraception face real teratogenic risk if they conceive while on these medications. A telehealth platform is not best positioned to manage reproductive counseling, contraceptive optimization, and AOM discontinuation planning together.

ACOG's 2023 guidance on obesity in pregnancy recommends against initiating GLP-1 agonists in pregnancy and advises preconception discontinuation [12]. Patients planning pregnancy should work with both their OB-GYN and an obesity medicine specialist.

Patient Profile 6: Cardiovascular Disease Requiring Close Monitoring

Semaglutide reduces major adverse cardiovascular events (MACE) in patients with established cardiovascular disease. The SELECT trial (N=17,604) showed a 20% reduction in MACE with semaglutide 2.4 mg vs. Placebo over a median 34.2 months [13]. This is genuinely good news for high-risk patients.

However, "high-risk" patients with recent MI, unstable angina, or heart failure with reduced ejection fraction (HFrEF) benefit from cardiologist co-management during AOM initiation, not because GLP-1s are harmful in these patients, but because weight loss itself produces hemodynamic changes that require medication adjustments. Beta-blockers, diuretics, and antihypertensives may need dose reductions as blood pressure falls.

Heart Failure With Preserved Ejection Fraction (HFpEF)

The STEP-HFpEF trial (N=529) showed that semaglutide 2.4 mg produced meaningful improvements in KCCQ clinical summary score and 6-minute walk distance in patients with HFpEF and BMI 30 or above [14]. This trial was conducted under close cardiologist supervision with regular echocardiography and clinical assessment. A telehealth model does not replicate that level of monitoring.

Patients with any diagnosed heart failure should have cardiology involvement in their AOM plan, regardless of which platform initiates it.

Patient Profile 7: Severe Renal or Hepatic Impairment

Semaglutide does not require dose adjustment for renal impairment per its FDA label, but GI side effects (nausea, vomiting, diarrhea) can precipitate dehydration and acute kidney injury in patients with CKD stage 3b or worse [1]. Bupropion and naltrexone both accumulate with hepatic impairment; bupropion is contraindicated in patients with severe hepatic cirrhosis [2].

A patient with CKD stage 4 or Child-Pugh class C cirrhosis needs nephrology or hepatology input before starting any of these agents. Lab values, creatinine, eGFR, LFTs, should be current before initiation. Found's async intake model may not require recent labs.

A Decision Framework: Found vs. Specialist Care

Use this as a starting-point guide, not a clinical decision tool. Any patient with complexity that spans multiple categories below should see an obesity medicine specialist (board certification available through ABOM, abom.org) or an endocrinologist.

Found is likely appropriate for patients who meet all of:

• BMI 27 or above with at least one weight-related comorbidity, or BMI 30 or above, per FDA criteria [1]
• No personal or family history of MTC or MEN2
• No active eating disorder
• Stable psychiatric history with no MAOI use
• No prior pancreatitis or significant GI disease
• Not pregnant, breastfeeding, or planning pregnancy within 6 months
• No severe renal or hepatic impairment (eGFR above 30, no cirrhosis)
• Willing to engage with required follow-up visits

Found is likely not the right fit for patients with:

• Any of the contraindications listed in the FDA labels for their prescribed medications [1][2][3]
• Active eating disorder requiring multidisciplinary care
• Unstable psychiatric illness or MAOI use
• Recent MI, unstable angina, or heart failure requiring cardiology co-management
• CKD stage 4 or worse, or decompensated liver disease
• Pregnancy, or planned conception within 2 months
• Complexity requiring subspecialist involvement before AOM initiation

How Found Complaints Break Down

Consumer complaints on Found, based on BBB filings and Trustpilot reviews as of early 2025, fall into three recurring categories:

Billing and Subscription Disputes

These are the most common complaint type. Patients report difficulty canceling recurring charges after stopping medication. While frustrating, this is an operational issue, not a clinical safety finding. Patients should confirm cancellation policies in writing before starting.

Medication Delays and Supply Chain Issues

Compounded semaglutide was widely available during the 2023-2024 shortage period. FDA declared the shortage resolved for Wegovy in May 2024, which affected compounding availability [15]. Patients who received compounded semaglutide through third-party pharmacies partnered with telehealth platforms should confirm their current prescription is for FDA-approved product.

Lack of Specialist Referral

A smaller but clinically important subset of complaints describes patients with complex conditions who felt their intake clinician did not flag the need for specialist involvement. This aligns with the structural limitation of async telehealth described throughout this article.

What AACE and Obesity Medicine Guidelines Say About Telehealth Prescribing

The AACE 2023 Obesity Clinical Practice Guideline states that treatment of obesity "requires individualized, evidence-based, and comprehensive medical evaluation" [5]. The Obesity Medicine Association (OMA) supports telehealth as a delivery model but emphasizes that clinical thoroughness should not be sacrificed for convenience.

"The use of telehealth for obesity management is appropriate when it ensures equivalent clinical rigor to in-person care, including thorough history-taking, medication safety review, and structured follow-up," according to OMA's position statement on telehealth and obesity care [16].

The key phrase is "equivalent clinical rigor." For the patient profiles described in this article, that rigor may not be achievable in a 15-minute async intake.

The Weight Regain Problem After Stopping

Patients considering any GLP-1 platform should understand that these medications require indefinite use to maintain effect. STEP-4 (N=803) showed that patients who discontinued semaglutide after 20 weeks regained an average of 6.9% body weight by week 68, reversing roughly two-thirds of their initial loss [4]. The SURMOUNT-4 extension trial (N=670) showed similar durability dependence for tirzepatide [17].

This is not a Found-specific issue. It applies to every platform and every prescriber. A telehealth model that does not build in long-term follow-up infrastructure creates a risk that patients will discontinue when side effects arise, face supply disruptions, or encounter billing problems, and regain weight without a clinical plan in place.

Patients should ask any platform, including Found, what happens to their care plan if they need to pause or stop medication.